Zeleciment basivarsen

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameZeleciment basivarsen
Drug Alias Namez-basivarsenDyne101Dyne-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody-Oligonucleotide conjugate
Mechanisms of ActionMyotonin-protein kinase inhibitors
TargetsMyotonin-protein kinase
Therapy Area/IndicationsMyotonic Dystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsNew Zealand +[9
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesDyne Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDyne Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMyotonic Dystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A